New drug ATG-022 enters human testing for Hard-to-Treat cancers
NCT ID NCT05718895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three weeks, and researchers will also watch for any signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATG-022 (a drug given by IV every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 156 participants, focused on finding a safe dose. It is too soon to know if ATG-022 will shrink tumors or improve survival, and there may be side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, China
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
-
Cabrini Health Limited
RECRUITINGMalvern, Australia
Contact Email: •••••@•••••
-
Cancer Research SA Pty Ltd
COMPLETEDAdelaide, Australia
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
-
Gansu provincial cancer hospital [recruiting]
RECRUITINGLanzhou, China
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, China
-
Integrated Clinical Oncology Network Pty Ltd (Icon)
RECRUITINGSouth Brisbane, Australia
-
Jinan Central Hospital
RECRUITINGJinan, China
-
Liaoning Cancer Hospital
RECRUITINGShenyang, China
-
Shanxi provincial cancer hospital
RECRUITINGTaiyuan, China
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
-
The First Affiliated Hospital of Zhenghzou University
RECRUITINGZhengzhou, China
-
The First affiliated hospital of Xi'An Jiao Tong Ubiversity
RECRUITINGXi'an, China
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiangzhuang, China
-
Tianjin Medical Universuty Cancer Institute & Hospital
RECRUITINGTianjin, China
-
Tongren Hospital Shanghai
RECRUITINGShanghai, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?